A new investigational medication called asundexian has demonstrated the ability to reduce the risk of a second stroke by 26% when combined with standard blood-thinning therapy, without increasing dangerous bleeding complications. This breakthrough comes from a large international trial presented at the American Stroke Association's International Stroke Conference 2026, and it addresses a critical gap in stroke prevention for the nearly 1 in 4 stroke survivors who experience another stroke. Why Is Preventing Second Strokes So Challenging? Stroke survivors face a daunting reality: current prevention strategies have significant limitations. Standard antiplatelet therapy, most commonly aspirin, works by preventing blood platelets from sticking together and forming clots. However, doctors have struggled to improve upon this approach because adding other blood-thinning medications typically increases the risk of bleeding inside the brain or elsewhere in the body. According to the American Stroke Association's 2021 guidelines, dual antiplatelet therapy, which combines two blood-thinning medications, is recommended only for very specific patients with early-arriving minor strokes or high-risk transient ischemic attacks (TIAs), and it is not recommended for long-term use. This leaves many stroke survivors with limited options for additional protection against a second stroke. "Antiplatelet therapy has limited effectiveness in preventing recurrent stroke because of bleeding risks. Previous efforts to improve outcomes by adding other anticlotting or blood thinning medications have not succeeded due to the increased risk of bleeding, lack of benefit or both," said Mike Sharma, principal investigator of the study and Michael G. Degroote Chair in Stroke Prevention at McMaster University. Mike Sharma, M.D., M.Sc., Principal Investigator, McMaster University How Does Asundexian Work Differently? Asundexian represents a novel approach to stroke prevention by targeting a specific clotting protein called Factor XI (FXIa), which is involved in producing large blood clots that can block blood vessels. Unlike other anticoagulants such as rivaroxaban and apixaban, which inhibit a different clotting protein called Factor Xa, asundexian does not increase the risk of bleeding. This unique safety profile is based on a natural experiment in human biology: people born with a genetic deficiency of Factor XI have a lower risk of ischemic stroke and rarely experience spontaneous bleeding. This observation gave researchers confidence that targeting Factor XI could prevent clots without the bleeding complications associated with other blood-thinning approaches. What Did the OCEANIC-STROKE Trial Show? The OCEANIC-STROKE study was a Phase III international trial that enrolled more than 12,300 stroke survivors across 702 sites in 37 countries between January 2023 and February 2025. Participants had recently experienced a mild to moderate ischemic stroke not caused by a heart condition such as atrial fibrillation, or they had a high-risk TIA. Participants were randomly assigned to receive either standard antiplatelet therapy plus daily asundexian or standard antiplatelet therapy plus a placebo. Neither patients nor researchers knew which treatment participants received during the trial. Researchers followed participants for 3 to 31 months and measured multiple outcomes. The results were compelling across several key measures: - Stroke Prevention: Adding asundexian to antiplatelet medication reduced the occurrence of ischemic stroke by 26%, and this reduction was consistent across all participants regardless of age, sex, cause of stroke, or severity of the first stroke - Disability Prevention: The medication reduced the occurrence of disabling strokes, which can have profound impacts on quality of life and independence - Safety Profile: Asundexian did not increase bleeding within the brain or major bleeding, and did not increase the occurrence of any serious adverse effects - Overall Cardiovascular Benefit: The medication lowered cardiovascular death, stroke of any type, heart attack, and major bleeding, indicating a broad benefit to patients beyond just preventing second strokes The study population consisted of 12,327 adults with an average age of 68, with 67% male participants. The strokes had various causes: 43% were assumed to be caused by plaque buildup in large arteries leading to the brain, 30% had strokes of undetermined cause, and 22% were thought to be due to blockages in small arteries feeding deep brain tissues. "Asundexian, when combined with standard antiplatelet therapy, helped reduce the chances of having another stroke without increasing the risk of bleeding. This benefit applies to all types of strokes, not just those caused by plaque build-up in large arteries. If approved by the FDA, asundexian could be widely used for patients who have had a non-cardioembolic stroke or a TIA," explained Sharma. Mike Sharma, M.D., M.Sc., Principal Investigator, McMaster University Steps to Understanding Your Stroke Prevention Options - Know Your Stroke Type: Understanding whether your stroke was caused by a blood clot, plaque buildup, small vessel disease, or an undetermined cause helps your doctor choose the most appropriate prevention strategy - Discuss Current Medications: Talk with your healthcare provider about your current antiplatelet therapy and whether you are a candidate for additional protection, especially if you have risk factors for a second stroke - Monitor for New Treatments: Ask your doctor about emerging medications like asundexian and whether you might be eligible for clinical trials or future FDA-approved therapies that could reduce your stroke risk - Track Bleeding Symptoms: Be aware of signs of unusual bleeding, such as nosebleeds, blood in urine or stool, or unexplained bruising, and report these to your healthcare provider immediately What Happens Next for Asundexian? Asundexian has not yet been approved in any country, but the U.S. Food and Drug Administration has granted the medication fast-track designation for its potential use in stroke prevention after ischemic stroke not caused by a blood clot originating in the heart. This designation accelerates the review process for medications that address serious conditions and fill an unmet medical need. It is important to note that the findings presented at the American Stroke Association's conference are preliminary. The study was presented as a research abstract, which has not undergone peer review. The results are considered preliminary until the full manuscript is published in a peer-reviewed scientific journal. Additionally, a substudy of OCEANIC-STROKE collected brain imaging and standardized MRI images from participants, and analysis of that data is not yet complete. These imaging results should provide further information on the impact of asundexian on both clotting and bleeding. For the nearly 1 in 4 stroke survivors who face the frightening prospect of another stroke, asundexian represents a potential breakthrough. By targeting a specific clotting protein without the bleeding risks associated with other blood-thinning approaches, this medication could offer a safer way to protect against recurrent strokes. While regulatory approval is still pending, the results from this large international trial suggest that stroke prevention may be entering a new era where doctors can offer more effective protection without forcing patients to choose between preventing clots and avoiding dangerous bleeding.
